Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemiaPatricia Stow, Dario Campana, Laura Key et al.|Blood|2010Cited by 159
A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcomeElaine Coustan‐Smith, Dario Campana, Raul C. Ribeiro et al.|Blood|2006Cited by 132
Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapyMelissa Hines, Aimee C. Talleur, Camille Keenan et al.|British Journal of Haematology|2021Cited by 122
Acute respiratory infections in children and adolescents with acute lymphoblastic leukemiaHana Hakim, Sima Jeha, Ronald H. Dallas et al.|Cancer|2015Cited by 73
Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with TisagenlecleucelJonas W. Ravich, Aimee C. Talleur, Sujuan Huang et al.|Transplantation and Cellular Therapy|2021Cited by 42